METIS TECHBIO-P (ASX: 07666) has announced that the over-allotment option detailed in the prospectus has been exercised in full. The overall coordinator, acting for itself and on behalf of the international underwriters, exercised the option on Friday, June 5, 2026.

This exercise involves a total of 30.184 million H shares, representing 15% of the total number of shares initially available under the global offering before any over-allotment option was exercised. These shares will be issued and allotted by the company at a price of HK$10.50 per H share.

This price is the same as the offer price per H share under the global offering, excluding a 1.0% brokerage commission, a 0.0027% SFC transaction levy, a 0.00565% HKEx trading fee, and a 0.00015% FRC transaction levy. The Stock Exchange of Hong Kong has granted approval for the listing and trading of these over-allotted shares.

The over-allotted shares are expected to commence trading on the Main Board of the Exchange at 9:00 a.m. on Wednesday, June 10, 2026. This action also marks the conclusion of the stabilization period and the associated stabilizing actions.